Journal of the Endocrine Society内分泌学会杂志
Journal of the Endocrine Society(英文缩写 J ENDOCR SOC),ISSN 2472-1972,eISSN 2472-1972,中文译名:内分泌学会杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-10-01 至 2026-09-30，按本站收录文献的发表日期统计。
期刊介绍
Journal of the Endocrine Society 最新收录文献
-
1. Correction to: "Adherence to Daily Growth Hormone Therapy in Japan: Real-World Data from the Melon Nikki™ App and Device".
PMID:日期:2026-09-24[This corrects the article DOI: 10.1210/jendso/bvag113.].
-
2. The effect of time-restricted eating accompanied by weight loss on thyroid function in adults with type 2 diabetes.
PMID:日期:2026-09-23Time-restricted eating (TRE) is a lifestyle intervention associated with beneficial cardiometabolic effects. The impact of TRE-induced weight reduction on thyroid hormonal responses is not well elucidated. To evaluate the effects of TRE accompanied by weight loss on thyroid function in adults with obesity and type 2 diabetes (T2DM). We performed an exploratory analysis of a randomized, crossover, open-label study in adults with obesity and T2DM who underwent 2 dietary interventions: TRE and standard lifestyle. Each intervention period lasted 6 weeks. Thyroid function was assessed by TSH, free T4 (fT4), free T3 (fT3), and reverse T3 (rT3). Thirty-nine participants without known thyroid disease (age 56.3 years, 35.9% male, body mass index 32.4 ± 5.7 kg/m) were included. TRE induced significant weight loss (-2.93 kg) compared to the standard lifestyle period (0.59 kg) (mean differences between intervention periods of -3.50 kg ± 2.9; < .001). Despite this robust weight-lowering effect, there were no significant differences in TSH (0.49 mUI/L ± 3.0; = .32), fT3 (-0.57 pmol/L ± 2.7; = .19), fT4 (fT4 -0.55 pmol/L ± 3.8; = .38), and rT3 (-0.94 ng/dL ± 5.9; = .350) between intervention periods. Reinforcing these findings, there was no treatment effect interaction on any thyroid function test evaluated. In addition, there was no significant change in the fT3: fT4 and fT3:rT3 ratios between treatment interventions. Despite inducing significant weight loss, TRE did not exert a significant effect on thyroid function in individuals with obesity and early T2DM.
-
3. Parental anxiety in differences of sex development and hypospadias: a psychosocial characterization.
PMID:日期:2026-09-16Parents of children with differences of sex development (DSD) and hypospadias experience significant psychological distress, but the factors contributing to parental anxiety remain poorly understood. Identify psychosocial factors associated with anxiety among parents of children with urogenital conditions and compare anxiety levels to parents in other pediatric settings. Cross-sectional survey study. Pediatric subspecialty clinics at an academic medical center. One hundred and eight parents of children with urogenital conditions without established genetic diagnoses, compared with 346 parents from BabySeq, a newborn genomic sequencing trial (278 parents of healthy newborns, 68 parents of neonatal intensive care unit [NICU] infants). Anxiety symptoms (Generalized Anxiety Disorder 7-item scale [GAD-7]), stigma, and quality of life. Clinically significant anxiety (GAD-7 ≥ 5) was present in 33% of parents of children with urogenital conditions, similar to the rate in parents of NICU infants (34%) and significantly higher than in parents of healthy newborns (21%, = .03). Forty-one percent reported self-blame for their child's condition; 16% reported blaming their partners. Quality of life decreased with increasing stigma ( = .001), genital atypicality ( = .03), and anxiety scores ( = .04). Backward elimination and Least Absolute Shrinkage and Selection Operator regression with multiple imputation identified 4 key factors predicting increased anxiety: higher intolerance of uncertainty, increased parental health-related stress, lower educational level, and greater emotional stigma. Additional factors included greater genital atypicality, social isolation, and self-blame. Parents of children with urogenital conditions experience anxiety levels comparable to parents of infants in the NICU, despite their children being medically stable. Uncertainty intolerance and emotional stigma provide targets for clinical screening and early intervention.
-
4. Phenotyping and hierarchical clustering in genetically unresolved DSD identifies distinct multisystem clinical subgroups-a DSDgene study.
PMID:日期:2026-09-15A substantial proportion of individuals with differences of sex development (DSD) remain without an identifiable molecular diagnosis. Systematic phenotyping may reveal clinically relevant patterns and inform genomic investigation. To identify phenotypic patterns among individuals with genetically unresolved DSD and determine whether multisystem anomalies form distinct clinical clusters and exhibit overlap with established DSD-associated conditions. Data from the I-DSD Registry were analyzed for individuals with 46,XY or 46,XX DSD lacking a molecular diagnosis. A 3-part approach was used: (1) unsupervised hierarchical clustering based on Gower distance; (2) supervised phenotype-guided classification using reference profiles for NR5A1/SF-1 deficiency and P450 oxidoreductase deficiency (PORD); and (3) exploratory comparison with Human Phenotype Ontology (HPO)-derived profiles of established DSD-associated genes. Among 1391 screened individuals, 345 (24.8%) fulfilled inclusion criteria, including the presence of at least 1 additional organ anomaly, 83.8% had a 46,XY karyotype. The most frequent associated findings were small for gestational age (28.1%), cardiac anomalies (21.4%), central nervous system (CNS) (15.7%), and renal anomalies (14.5%). Unsupervised clustering identified 5 phenotypic groups, including craniofacial-dominant and CNS-dominant clusters. Phenotype-guided classification showed overlap with SF-1-deficiency-associated phenotypes in 11% of cases and with PORD-associated phenotypes in 22%. Comparison with HPO-derived profiles of 81 DSD-associated genes demonstrated phenotypic similarities between several clusters and known gene-associated anomaly spectra. Systematic phenotyping identifies recognizable patterns of multisystem involvement in genetically unresolved DSD. Several clusters overlap with established DSD-associated conditions and gene-specific anomaly profiles, supporting phenotype-driven surveillance, multidisciplinary care, and informing future genomic re-evaluation strategies.
-
5. Rethinking gonadotropin releasing hormone agonist suppression test: why it should be a gonadotropin releasing hormone antagonist suppression test.
PMID:日期:2026-09-11The gonadotropin-releasing hormone (GnRH) suppression test has traditionally used GnRH agonists to differentiate gonadotropin-dependent from gonadotropin-independent sex steroid production. Although physiologically sound, this approach is limited by an initial luteinizing hormone and follicle-stimulating hormone (FSH) flare and the prolonged interval required to achieve pituitary suppression. We revisit the physiologic basis of the traditional GnRH agonist suppression test and propose the hypothesis that GnRH antagonists may provide a more direct pharmacologic approach to diagnostic suppression testing. Unlike GnRH agonists, antagonists produce immediate competitive receptor blockade without an initial stimulatory flare, resulting in rapid suppression of pituitary gonadotropins. However, downstream testosterone and estradiol concentrations are expected to decline more gradually because of hormone synthesis and physiologic clearance. This modification, in theory, should be more efficient for suppression testing. However, the optimal timing of downstream hormone reassessment remains unknown and requires prospective clinical investigation. Antagonist-based suppression testing should therefore be regarded as a hypothesis-generating concept rather than an established clinical strategy. If prospectively validated, it may provide a practical refinement of conventional GnRH agonist-based suppression testing while preserving its physiologic foundation.
-
6. Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study.
PMID:日期:2026-09-09To evaluate the association of long-term, continuous tirzepatide use with cardiometabolic risk parameters and estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk in real-world practice. This multicenter retrospective observational study included 1028 adults with overweight or obesity who received weekly subcutaneous tirzepatide for at least 12 months within the Mayo Clinic Health System from June 2022 through May 2024. Atherosclerotic cardiovascular disease risk analyses included 275 individuals with complete baseline and 12-month follow-up data. Outcomes were changes in cardiometabolic parameters, estimated 10-year ASCVD risk, and ASCVD risk category. At 12 months, median total body weight loss (TBWL) was 12.6%. Fasting glucose, HbA1c, triglycerides, and alanine aminotransferase decreased by 19.5%, 16.0%, 8.5%, and 10.6%, respectively, whereas HDL-cholesterol increased by 11.3% (all .001). Mean 10-year ASCVD risk did not change significantly overall (mean relative change, -3.7%; = .18), but changes differed by TBWL category (analysis of variance, .001). Atherosclerotic cardiovascular disease risk decreased among individuals achieving 10% to 20% TBWL (-9.6%; = .009) and >20% TBWL (-14.2%; = .005), but not among those achieving <10% TBWL (+7.7%; = .22). Low-risk prevalence increased from 38.3% to 46.4% ( .001), with 11.7% transitioning from higher-risk categories to low risk. Continuous tirzepatide use for at least 12 months was associated with clinically meaningful improvements in cardiometabolic parameters. Reductions in estimated 10-year ASCVD risk were observed among individuals achieving at least 10% TBWL, supporting greater weight loss as an important marker of cardiovascular risk improvement.
-
8. Inflammation and polyendocrine metabolic ovarian syndrome: utilizing proteomics to unravel this link in adolescents.
PMID:日期:2026-09-03Polyendocrine metabolic ovarian syndrome (PMOS) affects 10% to 26% of adolescent females. Yet, its pathogenesis is poorly understood. Proteomics is a valuable tool to explore biological pathways underpinning PMOS and identify novel diagnostic/monitoring biomarkers. We undertook deep-phenotyping discovery proteomic profiling (nanoflow 2-dimensional liquid chromatography-quadrupole time-of-flight mass spectrometry with alternating low- and elevated-energy acquisition) on urine samples from a subset of a longitudinal adolescent PMOS cohort (n = 40). We compared the urinary proteome of adolescents (12-19 years, ≥1-year postmenarche) recruited from adolescent endocrinology/gynecology clinics with PMOS or insulin resistance (IR), and community-recruited age-, sex-, and puberty-matched controls. PMOS was defined by adolescent-specific criteria (irregular menstrual cycles and hyperandrogenism). Exclusion criteria included the combined oral contraceptive pill. Results were validated in the whole cohort with a multiplexed targeted proteomic panel. Discovery proteomic analysis identified 3793 proteins, of which 66 were differentially expressed in the PMOS cohort vs IR and controls (candidate PMOS biomarkers). Bioinformatic analysis revealed that almost half of the PMOS-associated biological pathways were related to inflammatory/immunological responses. The inflammatory response was the most significant biological process ( < .001). Targeted proteomic analysis of 89 known inflammatory-associated proteins validated this association. Multivariate analysis demonstrated a distinct inflammatory proteome in adolescent PMOS.Twenty inflammatory-associated proteins were differentially expressed in the PMOS cohort vs IR and control groups, with notable roles in oxidative stress and neuroinflammation. Six proteins were significantly different in PMOS compared with both IR and control cohorts. These analyses provide insight into the pathophysiology of PMOS, highlighting inflammatory processes as a prominent feature of adolescent PMOS and identifying several candidate novel noninvasive biomarkers and drug targets that need further validation.
-
9. Intermediate risk thyroid cancer management: physician survey.
PMID:日期:2026-09-03Variability exists in the use of radioactive iodine (RAI) treatment in intermediate-risk (IR) thyroid cancer. The study surveyed clinicians about their use of RAI in theoretical cases of patients with IR thyroid cancer. A survey presented patient cases with pathology results and 2 variations consisting of baseline thyroglobulin levels of ≤5 and >5 ng/mL. Respondents were queried as to their use of RAI therapy in each case. Univariate Bayesian cumulative ordinal regression models were used to evaluate the relationships between selected predictors and the response. Online survey. American Thyroid Association members. Participants responded regarding their management of 15 patient cases of IR thyroid cancer. Use of RAI therapy, consisting of no RAI or doses of ∼30, 40 to 74, 75 to 100, or >100 mCi. Members were surveyed in May and June, 2024. Using matched vignettes, respondents were more likely to recommend RAI doses of ≥30 mCi and more likely to recommend higher RAI doses in general when thyroglobulin levels were >5 ng/mL compared with ≤5 ng/mL (odds ratios [ORs] 2.89-18.28). Examining unadjusted associations within the case scenarios presented, the presence of lymph nodes measuring 0.2-3 cm, more than 5 positive lymph nodes, and lateral lymph nodes were associated with higher RAI dose recommendations (unadjusted ORs 2.33-26.16). Within the IR category, there were specific pathology and biochemical findings associated with greater likelihood of the clinician recommending RAI therapy. These findings may be instructive in understanding how these features are perceived to add to the risk of thyroid cancer recurrence.
-
10. Recombinant human thyrotropin reducing insulin resistance in patients with differentiated thyroid cancer.
PMID:日期:2026-09-03Postsurgical radioactive iodine (RAI) therapy is indicated for adults with differentiated thyroid cancer (DTC) who are at an intermediate-to-high risk of recurrence. Thyrotropin (TSH) stimulation to facilitate RAI uptake can be achieved by injection of recombinant human TSH (rhTSH) or thyroid hormone withdrawal (THW). This study aimed to compare the effects of rhTSH administration and THW programs on insulin resistance. This prospective observational study included 47 patients who received rhTSH injections and 29 patients who underwent THW. All participants underwent a baseline assessment 4 weeks before RAI administration and a follow-up assessment on the day of RAI administration. Blood samples were collected for laboratory analysis, and insulin resistance was assessed using the homeostasis model assessment of insulin resistance (HOMA-IR). Homeostasis model assessment of insulin resistance significantly decreased after rhTSH administration (from 1.5 [0.8, 1.7] to 1.1 [0.7, 1.4], = .004) and after THW (from 1.4 [0.9, 1.7] to 0.7 [0.5, 1.0], < .001). These changes in HOMA-IR were not significantly different between the rhTSH and THW groups (-0.3 [-0.8, 0.2] vs -0.5 [-1.1, -0.2], = .120). Logistic regression analysis identified a greater reduction in triglyceride levels (a decrease of ≥0.028 mmol/L) as an independent factor for HOMA-IR reduction (the decrease ≥0.4) in the rhTSH group (odds ratio = 6.064, 95% confidence interval: 1.428-25.757, = .015). The rhTSH administration program attenuates insulin resistance in patients with DTC. The magnitude of HOMA-IR reduction in the rhTSH administration program is not significantly different from that in the THW program.